Synaptophysin-like 2 expression correlates with lymph node metastasis and poor prognosis in colorectal cancer patients

Figure 3 Correlations of levels of synaptophysin-like 2 expression with Kirsten rat sarcoma BRAF^V600E, and P53 mutations from GSE103479 and levels of expression of the key target genes KDR, epidermal growth factor receptor, vascular endothelial growth factor A, CD274, PDCD1, and CTLA4 from Gene Expression Profiling Interactive Analysis. A: Association of synaptophysin-like 2 (SYPL2) expression with KRAS, BRAF^V600E, P53 mutation; B: Association of SYPL2 expression with KDR, epidermal growth factor receptor, vascular endothelial growth factor A, CD274, PDCD1, cytotoxic T-lymphocyte-associated protein 4. SYPL2: Synaptophysin-like 2; MT: Mutation type; WT: Wild type; EGFR: Epidermal growth factor receptor; VEGFA: Vascular endothelial growth factor A; CTLA4: Cytotoxic T-lymphocyte-associated protein 4.